enzyme replacement therapy for lysosomal storage diseases
DESCRIPTION
Dr. Maynard's lecture on novel new therapies for treating Lysosomal Storage diseases (presented on 3/18/10).TRANSCRIPT
![Page 1: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/1.jpg)
Enzyme Replacement Therapy for Lysosomal Storage Diseases
PHS Lecture Series Roy Maynard, MD
March 18, 2010
![Page 2: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/2.jpg)
2
Objectives
1. Understand the pathophysiology of lysosomal storage diseases
2. Identify lysosomal storage diseases amenable to enzyme replacement therapy
3. Understand the limitations of enzyme replacement therapy
4. Recognize side effects of IV enzyme replacement therapy
![Page 3: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/3.jpg)
3
What is a Lysosome?
• Spherical organelles, discovered 1949 • Contain enzymes (acid hydrolases) • Role in digestion “suicide sacs” • Low pH • Cells’ garbage disposal system
![Page 4: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/4.jpg)
4
Lysosomal Functions
• Phagocytosis • Endocytosis • Exocytosis • Autophagy • Foreign microbe destruction
![Page 5: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/5.jpg)
5
Cellular Biology
Desnick RJ, Schuchman EH. Nat Rev Genet. 2002 Dec;3(12):954-66. Erratum in Nat Rev Genet. 2003 Feb;4(2):157.
![Page 6: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/6.jpg)
6
Lysosomal Storage Diseases
• Mucopolysaccharidoses • GM2 gangliosidoses • Lipid storage disorders • Glycoproteinoses • Mucolipidoses • Leukodystrophies
![Page 7: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/7.jpg)
7
Pompe’s Disease
• Genetics – Autosomal recessive – Pan-ethnic 1/40,000 – 1/146,000 – Infantile and late onset forms – Glycogen storage disease type II – Acid alpha-glucosidase deficiency – Over 200 different mutations account for
clinical heterogeneity
![Page 8: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/8.jpg)
8
Pompe’s Disease Autosomal Recessive
http://www.pompe.com/en/healthcare-professionals/genetics-epidemiology.aspx. Accessed on March 16, 2010.
![Page 9: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/9.jpg)
9
Pompe’s Disease
• Clinical features infantile form – Normal birth history – Age at presentation 2–4 months – Muscle weakness, hypotonia – Macroglossia – Hypertrophic cardiomyopathy – Respiratory failure – Early death
![Page 10: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/10.jpg)
10
Infantile Pompe’s Disease Survival
http://scienceroll.com/2007/02/06/pompe-disease-a-rare-but-important-genetic-condition. Accessed on March 16, 2010.
![Page 11: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/11.jpg)
11
Pompe’s Disease
Head lag caused by muscle weakness
http://scienceroll.com/2007/02/06/pompe-disease-a-rare-but-important-genetic-condition/. Accessed on March 15, 2010.
![Page 12: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/12.jpg)
12
Pompe’s Disease
http://scienceroll.com/2007/02/06/pompe-disease-a-rare-but-important-genetic-condition/. Accessed on March 15, 2010.
Cardiomegaly in infant
![Page 13: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/13.jpg)
13
Pompe’s Disease
• Clinical features late onset form – Normal birth history – Heterogeneous (childhood, juvenile, adult) – Adult onset 2nd to 6th decade – Typically no severe cardiomyopathy – Progressive skeletal myopathy
![Page 14: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/14.jpg)
14
Pompe’s Disease • Diagnosis
– Low or absent acid alpha glucosidase (GAA) – Muscle, fibroblast biopsy (gold standard) – Histopath vacuoles PAS stain positive – EKG (conduction, arrythmias) – Elevated creatinine kinase – DNA mutation analysis – Elevated liver enzymes
![Page 15: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/15.jpg)
15
Pompe’s Disease • Pathophysiology
– Accumulation glycogen in liver, heart, skeletal muscle, smooth muscle in GI tract, ear
– Large glycogen deposits in muscle cells (cardiac, skeletal, smooth) impair muscle fiber contraction
– Ultimately there is gross muscle hypertrophy due to increased glycogen storage at the expense of muscle atrophy and destruction
![Page 16: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/16.jpg)
16
Glycogen Buildup in Pompe Disease
http://www.mda.org/publications/quest/q161RescuedLives.html. Accessed on March 15, 2010.
![Page 17: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/17.jpg)
17
Electron Micrograph of Pompe Affected Muscle Cell
http://www.pompe.com/en/healthcare-professionals/overview/pathology.aspx. Accessed on March 15, 2010.
![Page 18: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/18.jpg)
18
Pompe’s Disease
• Treatment – Supportive
• Respiratory • Nutritional • Musculoskeletal/rehab • Cardiac
![Page 19: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/19.jpg)
19
Pompe’s Disease • Enzyme replacement therapy
– Alpha-glucosidase (GAA) – 1960’s enzyme replacement attempted – 2006 recombinant GAA available – IV dosing every 2 weeks – Early treatment – better outcome – Cell-surface receptors (mannose) plays a role in
endocytosis
• Mannose-6-phosphate (M6P) tag on enzymes
![Page 20: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/20.jpg)
20
Myozyme Production
Production of acid a-glucosidase in Chinese hamster ovary (CHO-) cells and in the milk of transgenic rabbits.
http://www.pompecenter.nl/en/?History. Accessed on March 16, 2010.
![Page 21: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/21.jpg)
21
Pompe’s Disease with Mannose 6-phosphate Tags
http://www.mda.org/publications/quest/q76resup.html. Accessed on March 15, 2010.
![Page 22: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/22.jpg)
22
Cellular Biology
http://www.mda.org/publications/quest/q102pompe.html. Accessed on March 15, 2010.
![Page 23: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/23.jpg)
23
Pompe’s Disease • Outcome after ERT
– Decrease glycogen in tissues – Improved quality and quantity of life – Decreased ventilator days – Study n=18, enrolled <7 mths/age
• 3 needed vent within 12 mths, 4 more needed vent beyond 12 mths treatment and 2/4 died
• 2/9 that had increased motor gains lost ground
– Decrease in LV size (no correlation to clinical outcome)
Kishnani PS, Corzo D, Leslie ND, et al. Pediatr Res. 2009 Sep;66(3):329-35.
![Page 24: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/24.jpg)
24
Pompe’s Disease Outcomes • French study
– N=21, 3–43 months age (median 13 mths) – Treated median 120 weeks – 71% alive study end – 44% of vent free patients at time of enrollment
remained vent free – Death reduced 79% – Vent risk reduced 58% – 86% functional independence skills (5 walking) – 52% infusion-associated reactions – 95% IgG antibodies
Nicolino M, Byrne B, Wraith JE, et al. Genet Med. 2009 Mar;11(3):210-9.
![Page 25: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/25.jpg)
25
Complications of Enzyme Replacement Therapy (Pompe’s)
• Life-threatening anaphylaxis/cardiac arrest – 1% • Allergic reaction – 14 % • Infusion reaction – 51% • 89% anti-IgG against GAA (higher incidence of
reactions in these patients and less efficacy of GAA)
• Serum sickness in IgG positive patients • Reactions can occur any time up to 2 hours after
infusion
![Page 26: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/26.jpg)
26
Complications of Enzyme Replacement Therapy (Pompe’s)
• 100% of patients had adverse events – Fever – Decrease oxygen sats – Tachycardia – Cyanosis – Hypotension – Rash, urticaria, flushing, pallor – Bronchospasm
![Page 27: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/27.jpg)
27
Gaucher’s Disease • Sometimes called glucocererebrosidase deficiency • Most prevalent metabolic storage disorder • Lipid storage disorder • Accumulation of glucosylceramide • Spleen, bone, and liver • Enzyme replacement since 1994 • Genetics autosomal recessive • 1/50,000 births, European Jewish population
![Page 28: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/28.jpg)
28
Gaucher’s Disease
• Clinical signs and symptoms – Easy bruising and bleeding – Fatigue – Anemia – Weak bones and fractures – Bone and joint pain – Hepatospleenomegaly
![Page 29: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/29.jpg)
29
Gaucher’s Disease
• Diagnosis – DNA mutation analysis chromosome 1 – Enzyme levels in blood or fibroblasts – Deficient glucocerebrosidase
![Page 30: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/30.jpg)
30
Gaucher’s Disease
![Page 31: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/31.jpg)
31
Gaucher’s Disease
http://wikidoc.org/images/thumb/e/e9/Gaucher_disease_004.jpg/400px-Gaucher_disease_004.jpg. Accessed on March 16, 2010.
![Page 32: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/32.jpg)
32
Gaucher’s Disease
• Enzyme replacement therapy – Cerezyme – Administered IV usually q 2 weeks – Allergic reactions – Reduction in symptoms – 13.8% adverse events – 1% < anaphylaxis
![Page 33: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/33.jpg)
33
Fabry’s Disease • Alpha galactosidase A deficiency • Accumulates glycolipid – globotriaosylceramide
(GL-3) • Blood vessels (vascular endothelium) • Genetics
– X-linked recessive – Males>females – 1/40,000–60,000 males – Survival mean age 41
![Page 34: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/34.jpg)
34
Fabry’s Disease and Hunter Syndrome X-linked Recessive
![Page 35: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/35.jpg)
35
Fabry’s Disease
• Clinical signs and symptoms – Renal failure 3rd decade – Cardiac – cardiomyopathy, hypertension – Skin – angiokeratomas, anhidrosis – Eyes – corneal issues – Neurostroke, fatigue, neuropathy – Pain in extremities
![Page 36: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/36.jpg)
36
Fabry’s Disease
• Diagnosis – Blood enzyme levels alpha-galactosidase – Chomosomal analysis of GLA gene for DNA
mutation
![Page 37: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/37.jpg)
37
Fabry’s Disease
• Treatment – Enzyme replacement therapy – Fabrazyme® (Genzyme Corp.) – Replagal® (Shire)
![Page 38: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/38.jpg)
38
Fabry’s Disease Outcome
• Decreased GL3 in tissues • May ameliorate disease expression
![Page 39: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/39.jpg)
39
Hurler’s Syndrome
• Mucopolysaccharidoses I (MPS I) – Autosomal recessive (chromosome 4)
1/100,000 births – Alpha-L-Iduronidase (Aldurazyme®)
• Aldurazyme® is manufactured by BioMarin Pharmaceutical Inc. and distributed by Genzyme Corp.
– Accumulate dermatan and heparin sulphate
![Page 40: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/40.jpg)
40
Hurler’s Syndrome • Clinical features
– Progressive deterioration – Large liver and spleen – Dwarfism – Hearing loss – Macroglossia – Mental retardation – Cloudy corneas – Limited joint movement – Respiratory abnormalities
![Page 41: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/41.jpg)
41
Hurler’s Syndrome
http://deti.msk.ru/plaxin_egor.jpg. Accessed on March 15, 2010.
![Page 42: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/42.jpg)
42
Hurler’s Syndrome
• Variations amenable to enzyme replacement therapy include Hurler-Scheie and Scheie Syndrome
• Aldurazyme®
![Page 43: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/43.jpg)
43
Hurler’s Syndrome
• Outcome – Increased walk distance – Increased FVC – Decreased liver and spleen size
![Page 44: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/44.jpg)
44
Hurler’s Syndrome • Adverse events
– 97% positive for IgG antibody – Anaphylaxis – 35% infusion-related reactions
• Fever • Chills • Hypotension • Tachycardia • Decreased oxygen sats
![Page 45: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/45.jpg)
45
Hunter Syndrome • Mucopolysaccharidosis II
– Deficiency iduronate-2-sulfatase (Elaprase® - Shire) – Dermatan and heparin sulfate – X-linked recessive (rare disease, >200 mutations) – Airway obstruction – Skeletal deformities – Cardiomyopathy – Neurological decline – Death 2nd decade
![Page 46: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/46.jpg)
46
Hunter Syndrome
http://davechidley.ca/wp-content/uploads/2009/02/szymon-cajmer900w.jpg. Accessed on March 15, 2010.
![Page 47: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/47.jpg)
47
Complications of Elaprase® Therapy for Hunter Syndrome
• Anaphylaxis (biphasic anaphylaxis 24 hrs after infusion)
• Respiratory distress, hypoxia, seizure, hypotension
• Fever – 63% • Headache – 59% • Joint pain – 31% • 51% have IgG against Elaprase®
![Page 48: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/48.jpg)
48
Hunter Syndrome
• Outcome – Increased walking capacity – Trend towards increased FVC – Decreased organ size
![Page 49: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/49.jpg)
49
Maroteaux-Lamy Syndrome
• Mucopolysaccharidosis VI (MPS VI) – Arylsulphatase B deficiency (Naglazyme® –
BioMarin Pharmaceutical Inc.) – Accumulate dermatan sulphate – Genetics
• Autosomal recessive • Rare disorder
![Page 50: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/50.jpg)
50
Maroteaux-Lamy Syndrome • Clinical signs and symptoms
– Coarse facial features – Skeletal damage – Hepatospleenomegaly – Corneal clouding – Cardiac valvular disease – Short stature – Normal intelligence – Respiratory
![Page 51: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/51.jpg)
51
Maroteaux-Lamy Syndrome
http://www.maroteaux-lamy.com/English/images/HCP/Patients.jpg. Accessed on March 15, 2010.
![Page 52: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/52.jpg)
52
Maroteaux-Lamy Syndrome Normal Storage Disorder
http://www.naglazyme.com/en/Images/Patients/StorageDisorderCells.JPG. Accessed on March 15, 2010.
Left: In a healthy cell with sufficient ASB activity, lysosomes constitute a negligible portion of cellular volume (about 1%).15
Right: In an MPS cell, lysosomes, replete with excess GAG, increase in both size and number, crowding the nucleus and other critical organelles, engorging the cell.
![Page 53: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/53.jpg)
53
Maroteaux-Lamy Syndrome
• Treatment – Palliative – Bone marrow transplant – Enzyme replacement therapy
• Naglazyme®
• Approved in 2005 • IV administration once/week
![Page 54: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/54.jpg)
54
Maroteaux-Lamy Syndrome • Initial reactions occurred as late as week 55 • The most frequent serious adverse events
related to Naglazyme® occurring during infusions included urticaria of the face and neck, bronchospasm, respiratory distress, and apnea.
• Almost all patients develop IgG antibodies
![Page 55: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/55.jpg)
55
Maroteaux-Lamy Syndrome
• Outcome – Improved walking and stair climbing ability – Decreased joint pain – No change in facial features or skeletal
deformities
![Page 56: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/56.jpg)
56
Treatment of Adverse Events
• Stop infusion or slow down infusion • Steroids • Antihistamines • Epinephrine • B-agonist nebulizer • Antipyretics
![Page 57: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/57.jpg)
57
Lysosomal Storage Diseases Conclusions
• Orphan disease for many, not funded • Enzyme replacement therapy very expensive • Long-term outcomes largely unknown • Limited results with CNS disease • Not curative • Difficult to target specific tissue (e.g. skeletal
muscle in Pompe’s Disease) • Tissues involved may not sufficiently remodel,
need to diagnose early for best results
![Page 58: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/58.jpg)
58
Future Considerations
• CNS penetration • Improved tissue-specific penetration • Stem cell transplant • Endogenous enzyme modulation • Gene therapy • In the future, more genetic diseases
amendable to enzyme replacement therapy will be discovered.
![Page 59: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/59.jpg)
59
Essentials of Successful Home Treatment Program
• Careful patient selection • Experienced home infusion team • Detailed management plan for potential
anaphylaxis and infusion-associated reactions
![Page 60: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/60.jpg)
60
Journal References • Burton BK, Wiesman C, Paras A, Kim K, Katz R. Mol Genet
Metab. 2009 Jul;97(3):234-6. Epub 2009 Apr 21. • Desnick RJ, Schuchman EH. Nat Rev Genet. 2002
Dec;3(12):954-66. Erratum in Nat Rev Genet. 2003 Feb;4(2):157. • Kishnani PS, Corzo D, Leslie ND, et al. Pediatr Res. 2009
Sep;66(3):329-35. • Nicolino M, Byrne B, Wraith JE, et al. Genet Med. 2009
Mar;11(3):210-9. • Roscoe O Brady. Annual Review of Medicine. 2006;57: 283-96.
60
![Page 61: Enzyme Replacement Therapy for Lysosomal Storage Diseases](https://reader034.vdocument.in/reader034/viewer/2022051411/546665d6af795969458b4e8b/html5/thumbnails/61.jpg)
61
Suggested Reading
• Kishnani PS, Steiner RD, Bali D, Berger K, et al: Pompe disease diagnosis and management guideline. Genet Med. 2006 May;8(5):267-88. No abstract available. Erratum in: Genet Med. 2006 Jun;8(6):382.
• Muenzer J, Wraith JE, Clarke LA: Mucopolysaccharidosis I: management and treatment guidelines. International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Pediatrics. 2009 Jan;123(1):19-29.